Compare two medicines for P. vivax malaria
Part of Infections clinical trials.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have P. vivax malaria only (confirmed by a rapid test), not P. falciparum
- You have had fever or a fever in the past 7 days
- You must be 18 or older and weigh more than 35 kg
- Your G6PD level must be high enough (at least 70% of the group average)
- You should not be pregnant or breastfeeding
- Your hemoglobin must be at least 8 g/dL and you have no history of drug allergy or blood cell breaking from these medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how the malaria medicine tafenoquine is processed in the bodies of young children with vivax malaria. It helps find the right dose for small children and ensures the treatment is safe and effective.
This study compares two medicines (tafenoquine and primaquine) taken with chloroquine to treat P. vivax malaria. It aims to see which is safer and works better in Indian participants aged 2 to 64.
This study tests the best dose of tafenoquine to treat people with symptoms from a malaria type called P. vivax and to help prevent it from coming back. You may be eligible if you recently had fever and meet specific blood and safety checks, especially G6PD level.
This trial tests a shorter course of the drug primaquine to prevent relapse of vivax malaria, a recurring type of malaria. It may offer a faster recovery with fewer doses.
This study tests a new combination of two medicines, SJ733 and tafenoquine, to see if it can safely and quickly cure vivax malaria. Vivax malaria can come back, so this treatment aims to prevent that relapse.
This Phase 3 trial tests whether giving malaria medicine to people in high-risk households (a “mass drug administration” campaign) can stop local relapses and eliminate vivax malaria. If you live close to a recent malaria case, you may be offered a preventive dose, based on age and medical safety checks.
Hear when a new Malaria trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.